First of all, I fully agree. I work at St. Michael's Hospital, which is an inner-city hospital in Toronto, and there are a lot of homeless folks around St. Mike's, many of whom have mental illnesses. My dad died of dementia, so I'm fully aware of the devastating effects of mental illness. I guess my comment about the cancer review that's been set up--the name of which I've forgotten--is that I don't think, in terms of the principles of how we make decisions about which drugs should be funded, that we should be differentiating between trying to treat cancer and mental health and then arthritis. Clearly some of these disorders kill people, and others affect their quality of life. We have to try to make sure we are treating all of these as importantly and equally as we can.
I don't have all the information on the CEDAC drugs before me that we reviewed, but I can remember a couple of mental health drugs, and we processed those exactly as we did the other drugs. So I don't think, at least from a CDR perspective, it's a matter of somehow speeding up the mental health drugs process compared to that for others. If there's a sense that the whole system is too slow, then we should talk about that, but I certainly don't think there's any discrimination, at least from where I sit, against drugs for mental health.